Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to -$1.8 million.

  • Arcutis Biotherapeutics' Free Cash Flow rose 9496.43% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.2 million, marking a year-over-year increase of 8018.87%. This contributed to the annual value of -$112.3 million for FY2024, which is 5462.31% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Free Cash Flow of -$1.8 million as of Q3 2025, which was up 9496.43% from $246000.0 recorded in Q2 2025.
  • Arcutis Biotherapeutics' Free Cash Flow's 5-year high stood at $246000.0 during Q2 2025, with a 5-year trough of -$80.4 million in Q1 2023.
  • For the 5-year period, Arcutis Biotherapeutics' Free Cash Flow averaged around -$43.5 million, with its median value being -$45.1 million (2024).
  • Per our database at Business Quant, Arcutis Biotherapeutics' Free Cash Flow plummeted by 12211.3% in 2021 and then skyrocketed by 10054.52% in 2025.
  • Arcutis Biotherapeutics' Free Cash Flow (Quarter) stood at -$52.0 million in 2021, then tumbled by 36.98% to -$71.2 million in 2022, then rose by 20.98% to -$56.2 million in 2023, then soared by 98.67% to -$748000.0 in 2024, then tumbled by 134.49% to -$1.8 million in 2025.
  • Its Free Cash Flow stands at -$1.8 million for Q3 2025, versus $246000.0 for Q2 2025 and -$31.0 million for Q1 2025.